FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a liquid formulation of a long-acting insulinotropic peptide conjugate, comprising a pharmaceutically effective amount of a long-acting insulinotropic peptide conjugate, where the insulinotropic peptide, which is a physiologically active peptide, is bound to the immunoglobulin Fc region; and an albumin-free stabiliser containing a buffer, a sugar alcohol and polysorbate 20. Where the insulinotropic peptide is selected from the group consisting of exendin-3, exendin-4, their precursors, agonists, derivatives, fragments, imidazoacetyl-oxendin-4 and combinations thereof. Group of inventions also relates to a method for producing said liquid formulation of a long-acting insulinotropic peptide conjugate.
EFFECT: group of inventions provides storage stability of insulinotropic peptide conjugates in high concentration.
30 cl, 12 ex, 4 dwg, 33 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULIN CONJUGATE | 2013 |
|
RU2670270C2 |
| SUSTAINED TYPE HUMAN GROWTH HORMONE PREPARATION | 2014 |
|
RU2683823C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE | 2011 |
|
RU2682720C2 |
| LIQUID COMPOSITION OF HUMAN GROWTH HORMONE WITH PROLONGED ACTION | 2011 |
|
RU2623026C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING CONJUGATE OF G-CSF | 2011 |
|
RU2519031C1 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
| COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2012 |
|
RU2606840C2 |
| PHARMACEUTICAL COMPOSITION FOR NON-ALCOHOLIC FATTY LIVER DISEASE PREVENTION OR TREATMENT | 2013 |
|
RU2635966C2 |
